A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

NCT01774747 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped This program was terminated for financial reasons

Conditions

Healthy

Interventions

DRUG: DSP-1053
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.